FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Douglas Ross

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Disorders

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Alex Man Lai Wu; Mingdong Yang; Charles V Clevenger; Pooja Dalvi; Patricia A Harper; Xiaoli Lu; Jason Matthews; David S Riddick; Douglas Ross; Shinya Ito
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Karthika Natarajan; Maria R Baer; Yi Xie; Douglas Ross
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Takeo Nakanishi; Douglas Ross
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Douglas Ross (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alex Man Lai Wu; Mingdong Yang; Charles V Clevenger; Pooja Dalvi; Patricia A Harper; Xiaoli Lu; Jason Matthews; David S Riddick; Douglas Ross; Shinya Ito
Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Molecular pharmacology 2013;83(2):377-88.
2012: Karthika Natarajan; Maria R Baer; Yi Xie; Douglas Ross
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
Biochemical pharmacology 2012;83(8):1084-103.
2012: Takeo Nakanishi; Douglas Ross
Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Chinese journal of cancer 2012;31(2):73-99.
2011: Douglas Ross; Carl A Schuetz; Deborah W Shpritz; Laura M Stapleton; Hongbin Fang; Timothy J Keay; Susan D Wolfsthal; Ann B Zimrin; David E Weissman
Creative solution for implementation of experiential, competency-based palliative care training for internal medicine residents.
Journal of cancer education : the official journal of the American Association for Cancer Education 2011;26(3):436-43.
2011: Karthika Natarajan; Kenneth S. Bauer; William T Beck; Takeo Nakanishi; Yi Xie; Douglas Ross
Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.
Biochimica et biophysica acta 2011;1809(7):295-305.
2011: Xiaonan Hou; Fei Huang; Joan M Carboni; Karen Flatten; Yan W Asmann; Cynthia Ten Eyck; Takeo Nakanishi; Jennifer D Tibodeau; Douglas Ross; Marco Gottardis; Charles Erlichman; Scott H Kaufmann; Paul Haluska
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Molecular cancer therapeutics 2011;10(1):117-25.
2010: Leslie M Tompkins; Haishan Li; Linhao Li; Caitlin Lynch; Yi Xie; Takeo Nakanishi; Douglas Ross; Hongbing Wang
A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.
Biochemical pharmacology 2010;80(11):1754-61.
2010: Xuetao Fan; Douglas Ross; Hiroshi Arakawa; Vadivel Ganapathy; Ikumi Tamai; Takeo Nakanishi
Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Biochemical pharmacology 2010;80(6):811-8.
2010: Kah Poh Tan; Bernice Wang; Mingdong Yang; Paul C Boutros; Jane Macaulay; Haibo Xu; Andrew I Chuang; Kazuhiro Kosuge; Mika Yamamoto; Shinichiro Takahashi; Alex M L Wu; Douglas Ross; Patricia A Harper; Shinya Ito
Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).
Molecular pharmacology 2010;78(2):175-85.
2010: T Nakanishi; Saranya Chumsri; Nazanin Khakpour; Angela Brodie; Brian Leyland-Jones; Anne W Hamburger; Douglas Ross; Angelika Burger
Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.
British journal of cancer 2010;102(5):815-26.
2010: Takeo Nakanishi; Douglas Ross; Keisuke Mitsuoka
Methods to evaluate transporter activity in cancer.
Methods in molecular biology (Clifton, N.J.) 2010;637():105-20.
2010: Douglas Ross; Takeo Nakanishi
Impact of breast cancer resistance protein on cancer treatment outcomes.
Methods in molecular biology (Clifton, N.J.) 2010;596():251-90.
2009: Sharmila Shankar; Rachel Davis; Karan P Singh; Razelle Kurzrock; Douglas Ross; Rakesh K Srivastava
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Molecular cancer therapeutics 2009;8(6):1596-605.
2009: Ken Shiozawa; Takeo Nakanishi; Ming Tan; Hongbin Fang; Wen-chyi Wang; Martin J Edelman; David Carlton; Ivana Gojo; Edward A Sausville; Douglas Ross
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1698-707.
2008: Hongbin Fang; Douglas Ross; Edward A Sausville; Ming Tan
Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
Statistics in medicine 2008;27(16):3071-83.
2008: Honggang Wang; Eun-Woo Lee; Lin Zhou; Peter C K Leung; Douglas Ross; Jashvant D Unadkat; Qingcheng Mao
Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells.
Molecular pharmacology 2008;73(3):845-54.
2008: Yingqiu Xie; Kexin Xu; Douglas E Linn; Xi Yang; Zhiyong Guo; Hermela Shimelis; Takeo Nakanishi; Douglas Ross; Hegang Chen; Ladan Fazli; Martin E Gleave; Yun Qiu
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.
The Journal of biological chemistry 2008;283(6):3349-56.
2007: Dong I Lee; Carlota Sumbilla; Myounghee Lee; Chidambaram Natesavelalar; Michael G Klein; Douglas Ross; Giuseppe Inesi; Arif Hussain
Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
Archives of biochemistry and biophysics 2007;464(1):19-27.
2007: Tamer E Fandy; Douglas Ross; Steven D Gore; Rakesh K Srivastava
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL.
Cancer chemotherapy and pharmacology 2007;60(3):313-9.
2006: Rachael Strong; Takeo Nakanishi; Douglas Ross; Catherine Fenselau
Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells.
Journal of proteome research 2006;5(9):2389-95.
2006: Anshul Gupta; Yang Dai; R Robert Vethanayagam; Mary F Hebert; Kenneth E Thummel; Jashvant D Unadkat; Douglas Ross; Qingcheng Mao
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Cancer chemotherapy and pharmacology 2006;58(3):374-83.
2006: John P O'Neill; Chidambaram Natesa Velalar; Dong I Lee; Bin Zhang; Takeo Nakanishi; Yao Tang; Florin Selaru; Douglas Ross; Meltzer Stephen J.; Arif Hussain
Thapsigargin resistance in human prostate cancer cells.
Cancer 2006;107(3):649-59.
2006: Takeo Nakanishi; Ken Shiozawa; Bret A Hassel; Douglas Ross
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression.
Blood 2006;108(2):678-84.
2006: Renee Royak-Schaler; Shahinaz Gadalla; Jeanne Parr Lemkau; Douglas Ross; Carla Alexander; Deborah Scott
Family perspectives on communication with healthcare providers during end-of-life cancer care.
Oncology nursing forum 2006;33(4):753-60.
2006: Takeo Nakanishi; Kimberly J Bailey-Dell; Bret A Hassel; Ken Shiozawa; Daniel M Sullivan; Joel Turner; Douglas Ross
Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
Cancer research 2006;66(10):5007-11.
2006: Renee Royak-Schaler; Chad DeYoung; Nazanin Khakpour; Douglas Ross; Katherine Tkaczuk; Shahinaz Gadalla
Readers respond to "balancing evidence-based medicine and cultural competence in the quest to end healthcare disparities".
MedGenMed : Medscape general medicine 2006;8(3):73; author reply 24.
2005: Judith E Karp; Antonino Passaniti; Ivana Gojo; Scott Kaufmann; Keith C Bible; Tushar S Garimella; Jacqueline Greer; Janet Briel; B Douglas Smith; Steven D Gore; Michael L Tidwell; Douglas Ross; John J Wright; A Dimitrios Colevas; Kenneth S. Bauer
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8403-12.
2005: Sharmila Shankar; Thiyam Ramsing Singh; Tamer E Fandy; Thitidaj Luetrakul; Douglas Ross; Rakesh K Srivastava
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
International journal of molecular medicine 2005;16(6):1125-38.
2005: Douglas Ross; Deborah Shpritz; Margaret M Hull; Olga Goloubeva
Long-term evaluation of required coursework in palliative and end-of-life care for medical students.
Journal of palliative medicine 2005;8(5):962-74.
2005: Yuexing Zhang; Xin-Wei Wang; Danijela Jelovac; Takeo Nakanishi; Myoung-Hee Yu; Damilola Akinmade; Olga Goloubeva; Douglas Ross; Angela Brodie; Anne W Hamburger
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(28):9890-5.
2005: Tamer E Fandy; Sharmila Shankar; Douglas Ross; Edward A Sausville; Rakesh K Srivastava
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Neoplasia (New York, N.Y.) 2005;7(7):646-57.
2005: Kenneth S. Bauer; Judith E Karp; Tushar S Garimella; Suhlan Wu; Ming Tan; Douglas Ross
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
Leukemia research 2005;29(3):263-71.
2005: Tushar S Garimella; Douglas Ross; Julie L Eiseman; J T Mondick; Erin Joseph; Takeo Nakanishi; S E Bates; Kenneth S. Bauer
Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.
Cancer chemotherapy and pharmacology 2005;55(2):101-9.
2005: Douglas Ross
Message for mid-term, 2005.
Journal of cancer education : the official journal of the American Association for Cancer Education 2005;20(2):65-6.
2004: Naoko Takebe; Xiangfei Cheng; Suhlan Wu; Kenneth S. Bauer; Olga Goloubeva; Robert G Fenton; Meyer Heyman; Aaron P Rapoport; Ashraf Badros; John Shaughnessy; Douglas Ross; Barry Meisenberg; Guido Tricot
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8301-8.
2004: Pui Lai Rachel Ee; Xiaolong He; Douglas Ross; William T Beck
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Molecular cancer therapeutics 2004;3(12):1577-83.
2004: Douglas Ross
Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome.
Best practice & research. Clinical haematology 2004;17(4):641-51.
2004: Attaya Suvannasankha; Hans Minderman; Kieran L O'Loughlin; Takeo Nakanishi; Laurie A Ford; William R Greco; Meir Wetzler; Douglas Ross; Maria R Baer
Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.
British journal of haematology 2004;127(4):392-8.
2004: Tushar S Garimella; Douglas Ross; Kenneth S. Bauer
Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;807(2):203-8.
2004: Douglas Ross; L Austin Doyle
Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance.
Cancer cell 2004;6(2):105-7.
2004: Attaya Suvannasankha; Hans Minderman; Kieran L O'Loughlin; Takeo Nakanishi; William R Greco; Douglas Ross; Maria R Baer
Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.
Leukemia 2004;18(7):1252-7.
2004: Partha Krishnamurthy; Douglas Ross; Takeo Nakanishi; Kimberly J Bailey-Dell; Sheng Zhou; Kelly E Mercer; Balázs Sarkadi; Brian P Sorrentino; John D Schuetz
The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.
The Journal of biological chemistry 2004;279(23):24218-25.
2004: Pui Lai Rachel Ee; Sitharthan Kamalakaran; Debra A Tonetti; Xiaolong He; Douglas Ross; William T Beck
Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.
Cancer research 2004;64(4):1247-51.
2004: Douglas Ross; Deborah Shpritz; Carla Alexander; Kennita Carter; Martin J Edelman; NANCY FRIEDLEY; Alnoor Hemani; Timothy J Keay; Susan C Roy; Henry J Silverman; David J Tasker; Daniel Timmel; Jack Schwartz; Susan D Wolfsthal
Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellows.
Journal of cancer education : the official journal of the American Association for Cancer Education 2004;19(2):81-7.
2004: Ken Shiozawa; Mikio Oka; Hiroshi Soda; Megumi Yoshikawa; Yoji Ikegami; Junji Tsurutani; Katsumi Nakatomi; Yoichi Nakamura; Seiji Doi; Takeshi Kitazaki; Yohei Mizuta; Kunihiko Murase; Hisahiro Yoshida; Douglas Ross; Shigeru Kohno
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
International journal of cancer. Journal international du cancer 2004;108(1):146-51.
2003: Takeo Nakanishi; L Austin Doyle; Bret A Hassel; Yuetong Wei; Kenneth S. Bauer; Suhlan Wu; David W Pumplin; Hongbin Fang; Douglas Ross
Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
Molecular pharmacology 2003;64(6):1452-62.
2003: L Austin Doyle; Douglas Ross
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene 2003;22(47):7340-58.
2003: Takeo Nakanishi; Judith E Karp; Ming Tan; L Austin Doyle; Todd Peters; Weidong Yang; David Wei; Douglas Ross
Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3320-8.
2003: Thomas Efferth; Erich Gebhart; Douglas Ross; Axel Sauerbrey
Identification of gene expression profiles predicting tumor cell response to L-alanosine.
Biochemical pharmacology 2003;66(4):613-21.
2003: Thomas Efferth; Axel Sauerbrey; Armin Olbrich; Erich Gebhart; Pia Rauch; H Oliver Weber; Jan G Hengstler; Marc-Eric Halatsch; Manfred Volm; Kenneth D Tew; Douglas Ross; Jens Oliver Funk
Molecular modes of action of artesunate in tumor cell lines.
Molecular pharmacology 2003;64(2):382-94.
2003: Zhe-Sheng Chen; Robert W Robey; Martin G Belinsky; Irina Shchaveleva; Xiao-Qin Ren; Yoshikazu Sugimoto; Douglas Ross; Susan E Bates; Gary Kruh
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
Cancer research 2003;63(14):4048-54.
2003: Rajeev Rajendra; Murugesan K Gounder; Ahamed Saleem; Jan H M Schellens; Douglas Ross; Susan E Bates; Patrick Sinko; Eric H Rubin
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Cancer research 2003;63(12):3228-33.
2003: Thomas Efferth; Axel Sauerbrey; Marc-Eric Halatsch; Douglas Ross; Erich Gebhart
Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Naunyn-Schmiedeberg's archives of pharmacology 2003;367(1):56-67.
2003: Judith E Karp; Douglas Ross; Weidong Yang; Michael L Tidwell; Yuetong Wei; Jacqueline Greer; Dean L Mann; Takeo Nakanishi; John J Wright; A Dimitrios Colevas
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):307-15.
2002: Thomas Efferth; Armin Olbrich; Axel Sauerbrey; Douglas Ross; Erich Gebhart; Michael Neugebauer
Activity of ascaridol from the anthelmintic herb Chenopodium anthelminticum L. against sensitive and multidrug-resistant tumor cells.
Anticancer research 2002;22(6C):4221-4.
2002: Paul A Seligman; Douglas Ross
Palliative Care Section.
Journal of cancer education : the official journal of the American Association for Cancer Education 2002;17(2):66-7.
2001: Susan E Bates; Robert W Robey; K Miyake; K Rao; Douglas Ross; Thomas Litman
The role of half-transporters in multidrug resistance.
Journal of bioenergetics and biomembranes 2001;33(6):503-11.
2001: Kimberly J Bailey-Dell; Bret A Hassel; L Austin Doyle; Douglas Ross
Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene.
Biochimica et biophysica acta 2001;1520(3):234-41.
2001: Douglas Ross; Carla Alexander
Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea.
American family physician 2001;64(6):1019-26.
2001: M Simons-Evelyn; Kimberly J Bailey-Dell; Jeffrey A Toretsky; Douglas Ross; Robert G Fenton; Dhan V Kalvakolanu; Aaron P Rapoport
PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells.
Blood cells, molecules & diseases 2001;27(5):825-9.
2001: Douglas Ross; Carla Alexander
Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting.
American family physician 2001;64(5):807-14.
2001: Shigeru Kawabata; Mikio Oka; Ken Shiozawa; Kazuhiro Tsukamoto; Katsumi Nakatomi; Hiroshi Soda; Minoru Fukuda; Yoji Ikegami; K Sugahara; Yasuaki Yamada; Shimeru Kamihira; L Austin Doyle; Douglas Ross; Shigeru Kohno
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Biochemical and biophysical research communications 2001;280(5):1216-23.
2001: Charles Erlichman; Scott A Boerner; C G Hallgren; R Spieker; X Y Wang; C David James; George L Scheffer; Marc Maliepaard; Douglas Ross; Keith C Bible; Scott H Kaufmann
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Cancer research 2001;61(2):739-48.
2001: Douglas Ross; H C Fraser; Jean S Kutner
Institutionalization of a palliative and end-of-life care educational program in a medical school curriculum.
Journal of palliative medicine 2001;4(4):512-8.
2001: Robert W Robey; Wilma Y Medina-Pérez; K Nishiyama; Tyler Lahusen; K Miyake; Thomas Litman; Adrian M Senderowicz; Douglas Ross; Susan E Bates
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(1):145-52.
2000: Susanne B Haga; Sidong Fu; Judith E Karp; Douglas Ross; D M Williams; William David Hankins; Frederick G. Behm; F W Ruscetti; M Chang; B Douglas Smith; David L Becton; Susana C Raimondi; Patricia E Berg
BP1, a new homeobox gene, is frequently expressed in acute leukemias.
Leukemia 2000;14(11):1867-75.
2000: Erin L Volk; K Rohde; M Rhee; J J McGuire; L Austin Doyle; Douglas Ross; Erasmus Schneider
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
Cancer research 2000;60(13):3514-21.
2000: Douglas Ross; Judith E Karp; T T Chen; L Austin Doyle
Expression of breast cancer resistance protein in blast cells from patients with acute leukemia.
Blood 2000;96(1):365-8.
2000: Thomas Litman; M Brangi; E Hudson; Patricia A Fetsch; Andrea Abati; Douglas Ross; K Miyake; James Resau; Susan E Bates
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
Journal of cell science 2000;113 ( Pt 11)():2011-21.
2000: George L Scheffer; Marc Maliepaard; Adriana C L M Pijnenborg; Margôt van Gastelen; Mariska C de Jong; Anouk B Schroeijers; Dorina M van der Kolk; J D Allen; Douglas Ross; Paul Van Der Valk; W S Dalton; J H M Schellens; Rik J Scheper
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Cancer research 2000;60(10):2589-93.
2000: Douglas Ross
Novel mechanisms of drug resistance in leukemia.
Leukemia 2000;14(3):467-73.
2000: Timothy J Keay; Carla Alexander; K McNally; B Crusse; R E Eger; C Hawtin; Nancy R Lowitt; Douglas Ross
Adult education program in palliative care for nursing facility physicians: design and pilot test.
Journal of palliative medicine 2000;3(4):457-63.
2000: Sridhar K Rabindran; Douglas Ross; L Austin Doyle; W Yang; Lee M Greenberger
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
Cancer research 2000;60(1):47-50.
1999: Douglas Ross; W Yang; Lynne V Abruzzo; W S Dalton; E Schneider; H Lage; M Dietel; Lee M Greenberger; SUSAN COLE; L Austin Doyle
Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Journal of the National Cancer Institute 1999;91(5):429-33.
1999: Adorjan Aszalos; K Thompson; Jun-Jie Yin; Douglas Ross
Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).
Anticancer research 1999;19(2A):1053-64.
1999: Douglas Ross; Timothy J Keay; Daniel Timmel; Carla Alexander; C Dignon; AM O'Mara; W O'Brien
Required training in hospice and palliative care at the University of Maryland School of Medicine.
Journal of cancer education : the official journal of the American Association for Cancer Education 1999;14(3):132-6.
1999: Paul A Seligman; C Dignon; Douglas Ross; P D Steen; Janet L Abrahm; P H Boston; F Ferris; J Foley; Paula Nelson-Marten; AM O'Mara; C F von Gunten; D E Weissman
Development of a teaching module for quality-of-life assessment of terminal patients. The AACE Multi-Institutional Palliative Cancer Education Section. American Association for Cancer Education.
Journal of cancer education : the official journal of the American Association for Cancer Education 1999;14(3):129-31.
1999: Paul A Seligman; Douglas Ross
Palliative care education--can we respond to the challenge?
Journal of cancer education : the official journal of the American Association for Cancer Education 1999;14(3):127-8.
1998: L Austin Doyle; W Yang; Lynne V Abruzzo; Tammy A Krogmann; Y Gao; Arun K Rishi; Douglas Ross
A multidrug resistance transporter from human MCF-7 breast cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(26):15665-70.
1998: Adorjan Aszalos; Douglas Ross
Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
Anticancer research 1998;18(4C):2937-44.
1997: Douglas Ross; Y Gao; W Yang; John Leszyk; J Shively; L Austin Doyle
The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen.
Cancer research 1997;57(24):5460-4.
1997: Douglas Ross; AM O'Mara; N Pickens; Timothy J Keay; Daniel Timmel; Carla Alexander; C Hawtin; W O'Brien; N Schnaper
Hospice and palliative care education in medical school: a module on the role of the physician in end-of-life care.
Journal of cancer education : the official journal of the American Association for Cancer Education 1997;12(3):152-6.
1996: L Austin Doyle; W Yang; Arun K Rishi; Y Gao; Douglas Ross
H19 gene overexpression in atypical multidrug-resistant cells associated with expression of a 95-kilodalton membrane glycoprotein.
Cancer research 1996;56(13):2904-7.
1996: R R Grauel; R Eger; R C Finley; C Hawtin; Timothy J Keay; W O'Brien; N Pickens; N Schnapper; Daniel Timmel; AM O'Mara; Douglas Ross
Educational program in palliative and hospice care at the University of Maryland School of Medicine.
Journal of cancer education : the official journal of the American Association for Cancer Education 1996;11(3):144-7.
1996: P Wills; Robert Hickey; Douglas Ross; D Cuddy; Linda H Malkas
A novel in vitro model system for studying the action of ara-C.
Cancer chemotherapy and pharmacology 1996;38(4):366-72.
1996: Douglas Ross; L Austin Doyle; Charles Alan Schiffer; Edward J Lee; Caroline E Grant; SUSAN COLE; Roger G Deeley; W Yang; Y Tong
Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Leukemia 1996;10(1):48-55.
1995: Douglas Ross; L Austin Doyle; W Yang; Y Tong; B Cornblatt
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Biochemical pharmacology 1995;50(10):1673-83.
1995: L Austin Doyle; Y Gao; W Yang; Douglas Ross
Characterization of a 95 kilodalton membrane glycoprotein associated with multi-drug resistance.
International journal of cancer. Journal international du cancer 1995;62(5):593-8.
1995: L Austin Doyle; Douglas Ross; J V Ordonez; W Yang; Y Gao; Y Tong; Chandra P Belani; J C Gutheil
An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
British journal of cancer 1995;72(3):535-42.
1995: Jean L Grem; F Geoffroy; P M Politi; D P Cuddy; Douglas Ross; D Nguyen; Seth M Steinberg; Carmen J Allegra
Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
Molecular pharmacology 1995;48(2):305-15.
1995: Douglas Ross; D P Cuddy
Consequences of 2',2'-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells.
Seminars in oncology 1995;22(4 Suppl 11):26-34.
1995: P F Lenehan; P L Gutiérrez; J L Wagner; N Milak; G R Fisher; Douglas Ross
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.
Cancer chemotherapy and pharmacology 1995;35(5):377-86.
1995: L Austin Doyle; Douglas Ross; R Sridhara; A T Fojo; S H Kaufmann; Edward J Lee; Charles Alan Schiffer
Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells.
British journal of cancer 1995;71(1):52-8.
1994: Douglas Ross; D P Cuddy
Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
Biochemical pharmacology 1994;48(8):1619-30.
1994: Douglas Ross; P J Wooten; Y Tong; B Cornblatt; C Levy; R Sridhara; Edward J Lee; Charles Alan Schiffer
Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
Blood 1994;83(5):1337-47.
1993: Douglas Ross; P J Wooten; R Sridhara; J V Ordóñez; Edward J Lee; Charles Alan Schiffer
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.
Blood 1993;82(4):1288-99.
1992: Douglas Ross; D P Cuddy; N Cohen; D R Hensley
Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine.
Cancer chemotherapy and pharmacology 1992;31(1):61-70.
1991: N A Cohen; Merrill J Egorin; S W Snyder; Bimal H Ashar; B E Wietharn; S S Pan; Douglas Ross; J Hilton
Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA.
Cancer research 1991;51(16):4360-6.
1991: Douglas Ross
Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia.
Current opinion in oncology 1991;3(1):21-9.
1991: D L de Valeriola; Douglas Ross; A Forrest; D P Cuddy; Merrill J Egorin
Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.
Cancer chemotherapy and pharmacology 1991;29(2):133-40.
1991: J E Gervasoni; Robert N Taub; M Rosado; S Krishna; V J Stewart; D M Knowles; Kapil N Bhalla; Douglas Ross; M A Baker; J Lutzky
Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.
Cancer chemotherapy and pharmacology 1991;28(2):93-101.
1990: Douglas Ross; S R Chen; D P Cuddy
Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.
Cancer research 1990;50(9):2658-66.
1989: B C Fox; Douglas Ross; A B Huang; Edward Gabrielson; Priscilla A Furth
Mycobacterial disease associated with aplastic anaemia.
The Journal of infection 1989;19(2):157-65.
1989: Douglas Ross; C C Joneckis; J V Ordóñez; A M Sisk; R K Wu; R E Hamburger AW Nora; Richard E. Nora
Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number.
Cancer research 1989;49(14):3776-82.
1989: Douglas Ross; B W Thompson; J V Ordóñez; C C Joneckis
Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content.
Cytometry 1989;10(2):185-91.
1989: D Y Hou; J V Ordonez; R J Cross; Douglas Ross; Y Maruyama
Killing lung cancer cells at cell-cycle phase by a new indium-111-bleomycin complex.
Journal of surgical oncology 1989;40(2):73-8.
1988: Douglas Ross; J V Ordóñez; C C Joneckis; J R Testa; B W Thompson
Isolation of highly multidrug-resistant P388 cells from drug-sensitive P388/S cells by flow cytometric cell sorting.
Cytometry 1988;9(4):359-67.
1988: Douglas Ross; C C Joneckis; T H Song; R K Wu
Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells.
Cancer research 1988;48(3):517-21.
1987: Douglas Ross; B W Thompson; C C Joneckis; S A Akman; Charles Alan Schiffer
Studies of ara-C metabolism in acute leukemia.
Seminars in oncology 1987;14(2 Suppl 1):182-91.
1986: Douglas Ross; C C Joneckis; Charles Alan Schiffer
Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.
Blood 1986;68(1):83-8.
1986: Douglas Ross; B W Thompson; C C Joneckis; S A Akman; Charles Alan Schiffer
Metabolism of ara-C by blast cells from patients with ANLL.
Blood 1986;68(1):76-82.
1985: S A Akman; Douglas Ross; C C Joneckis; B M Fox; N R Bachur
Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
Cancer treatment reports 1985;69(7-8):851-7.
1984: S A Akman; Douglas Ross; C C Joneckis; B M Fox; N R Bachur
Synergistic inhibition of human leukemia cell growth by deoxyguanosine and 1-beta-D-arabinofuranosylcytosine.
Biochemical pharmacology 1984;33(7):1059-63.
1984: Douglas Ross; S A Akman; C C Joneckis; E Yang; N R Bachur
Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by deoxyguanosine.
Cancer research 1984;44(4):1530-5.
1983: N Biswal; U Ko; S Akman; Douglas Ross; A Pollak; E Cimino
Persistence of herpes simplex virus type-2 genome in a human leukemic cell line.
Biochimica et biophysica acta 1983;740(3):271-81.
1983: I W Dimery; Douglas Ross; J R Testa; S K Gupta; R L Felsted; A Pollak; N R Bachur
Variation amongst K562 cell cultures.
Experimental hematology 1983;11(7):601-10.
1981: Douglas Ross; S A Akman; A W Schrecker; N R Bachur
Effects of deoxynucleosides on cultured human leukemia cell growth and deoxynucleotide pools.
Cancer research 1981;41(11 Pt 1):4493-8.
1981: S A Akman; Douglas Ross; H Rosen; C Salinger; P A Andrews; F E Chou; N R Bachur
Growth inhibition by thymidine of leukemic HL-60 and normal human myeloid progenitor cells.
Cancer research 1981;41(6):2141-6.
1980: Douglas Ross; A Pollak; S A Akman; N R Bachur
Diurnal variation of circulating human myeloid progenitor cells.
Experimental hematology 1980;8(7):954-60.
1979: Douglas Ross; P H Wiernik; P S Sarin; J Whang-Peng
Loss of terminal deoxynucleotidyl transferase (TdT) activity as a predictor of emergence of resistance to chemotherapy in a case of chronic myelogenous leukemia in blast crisis.
Cancer 1979;44(5):1566-70.
1979: Joseph Aisner; Douglas Ross; P H Wiernik
Tamoxifen in advanced male breast cancer.
Archives of internal medicine 1979;139(4):480-1.
1975: Douglas Ross; D P Groth; J M Kinkade
Effects of urinary proteins from certain leukemics upon macromolecular synthesis and enzyme levels in bone marrow cultures.
The Journal of biological chemistry 1975;250(22):8829-33.